Using 2007–2016 data from NHANES, a nationally representative survey of American men and women, Chen-Xu et al. set out to estimate the current prevalence rates and decadal trends of gout and hyperuricemia in the U.S.
Search results for: physical function
Upadacitinib Monotherapy Effective in Refractory Rheumatoid Arthritis
NEW YORK (Reuters Health)—Monotherapy with the JAK1-selective inhibitor upadacitinib is effective in patients with active rheumatoid arthritis who have an inadequate response to methotrexate, according to results from the SELECT-MONOTHERAPY phase 3 trial. As many as two-thirds of patients with rheumatoid arthritis receiving methotrexate monotherapy fail to achieve satisfactory disease control. Oral therapy with upadacitinib…
New Tools for Myositis Diagnosis, Classification & Management
CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…
Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…
MRI-Guided Therapy Offers No Improvement Over Conventional Treat to Target for RA
New research does not support the use of a magnetic resonance imaging (MRI)-guided strategy for treating RA patients. The study found that among RA patients in remission, an MRI-guided treat-to-target strategy compared with a conventional treat-to-target strategy did not result in improved disease activity remission rates or reduced radiographic progression…
Destructive Arthritis: From Prevention to Progression to Remission
CHICAGO—Josef S. Smolen, MD, professor of internal medicine and chair of the Department of Rheumatology, Vienna General Hospital, Austria, presented the prestigious Paul Klemperer, MD, Memorial Lecture at the 2018 ACR/ARHP Annual Meeting. Dr. Smolen, whose work is frequently cited, created the treat-to-target strategy for rheumatoid arthritis (RA). Dr. Smolen began by noting a simple…
Tanezumab for OA Pain
In a recent study, tanezumab proved more effective than placebo in treating patients with moderate to severe pain caused by hip or knee osteoarthritis…
These Digital Tools Aren’t Just Hype, Can Actually Help Rheumatologists
CHICAGO—Every minute, it seems, a new digital tool is introduced in medicine. Whether it’s a new digital measuring stick, a new data-crunching system or a new app, the tech tools form an endless convoy of options. But are they worth it? Will they really help you do your job better? Will they help patients feel…
Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone
Health Canada has approved Erelzi, which is biosimilar to Enbrel (etanercept), for treating psoriatic arthritis in adults…
OA Patient-Reported Outcomes Positive for Intra-Articular Injection
In a recent Phase 2 clinical trial, patient-perceived pain and function measures improved with SM04690, an injectable, disease-modifying osteoarthritis treatment currently in development…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 81
- Next Page »